KR20260004528A - 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드 - Google Patents

길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Info

Publication number
KR20260004528A
KR20260004528A KR1020257040897A KR20257040897A KR20260004528A KR 20260004528 A KR20260004528 A KR 20260004528A KR 1020257040897 A KR1020257040897 A KR 1020257040897A KR 20257040897 A KR20257040897 A KR 20257040897A KR 20260004528 A KR20260004528 A KR 20260004528A
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding fragment
amino acid
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257040897A
Other languages
English (en)
Korean (ko)
Inventor
데니스 엘. 파우스트맨
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Publication of KR20260004528A publication Critical patent/KR20260004528A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020257040897A 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드 Pending KR20260004528A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862765284P 2018-08-20 2018-08-20
US62/765,284 2018-08-20
KR1020217008246A KR20210061350A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드
PCT/US2019/047330 WO2020041361A1 (en) 2018-08-20 2019-08-20 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008246A Division KR20210061350A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드

Publications (1)

Publication Number Publication Date
KR20260004528A true KR20260004528A (ko) 2026-01-08

Family

ID=69591189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257040897A Pending KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드
KR1020217008246A Ceased KR20210061350A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217008246A Ceased KR20210061350A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드

Country Status (8)

Country Link
US (2) US12624117B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840782A4 (cg-RX-API-DMAC7.html)
JP (2) JP7713880B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260004528A (cg-RX-API-DMAC7.html)
CN (1) CN112955179A (cg-RX-API-DMAC7.html)
AU (1) AU2019324134B2 (cg-RX-API-DMAC7.html)
CA (1) CA3109954A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020041361A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション T制御性細胞の増殖または枯渇方法
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
AU2016286108B2 (en) 2015-06-30 2021-03-11 Pfizer Inc. BTLA fusion protein agonists and uses thereof
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
WO2020041361A1 (en) * 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2021231922A1 (en) * 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
JP7895285B2 (ja) 2020-06-12 2026-07-27 ナンチン リーズ バイオラブス カンパニー,リミティド Tnfr2に結合する抗体およびその用途
IL299235A (en) * 2020-07-02 2023-02-01 Biolojic Design Ltd Antibodies against (TNFR2) and their uses
CN112159818B (zh) * 2020-08-20 2023-02-21 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
EP4281482A4 (en) * 2021-01-21 2025-04-30 The General Hospital Corporation ANTAGONIST ANTIBODIES OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
US20250043015A1 (en) * 2021-06-30 2025-02-06 Shenghe (China) Biopharmaceutical Co., Ltd. Anti-tnfr2 single domain antibody, and preparation method therefor and application thereof
CN116334768A (zh) * 2022-07-14 2023-06-27 上海肽盛医药有限公司 一种结构多样的多肽库及其构建方法和应用
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
SE8204382L (sv) 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
WO1986003751A2 (en) 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5059530A (en) 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4985241A (en) 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5370870A (en) 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6984380B1 (en) 1991-08-02 2006-01-10 Denise L. Faustman Treatment of diseases involving faulty MHC class I antigen complex presentation
WO1993002690A1 (en) 1991-08-02 1993-02-18 The General Hospital Corporation Diagnosis and treatment of autoimmune diseases
US5139481A (en) 1991-08-07 1992-08-18 The General Hospital Corporation Treatment for type II diabetes
US5843425A (en) 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
ES2168273T3 (es) 1992-04-23 2002-06-16 Sloan Kettering Inst Cancer Ligando para el receptor c-kit y metodos de uso del mismo.
US5939532A (en) 1993-09-07 1999-08-17 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies to ganglioside GM2
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5560908A (en) 1993-01-22 1996-10-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
WO1997008328A1 (en) 1995-08-30 1997-03-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Selective elimination of t cells that recognize specific preselected targets
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5874306A (en) 1996-12-12 1999-02-23 The Regents Of The University Of California Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells
AU6241698A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
WO1999029343A1 (en) 1997-12-09 1999-06-17 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6284879B1 (en) 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6165737A (en) 1998-04-16 2000-12-26 The University Of Texas System Board Of Regents DNA fragmentation factor involved in apoptosis
EP1077724A2 (en) 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
WO1999059632A1 (en) 1998-05-18 1999-11-25 Applied Research Systems Ars Holding N.V. Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
JP3589912B2 (ja) 1999-09-03 2004-11-17 泰久 福井 ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
WO2001044472A1 (en) 1999-12-16 2001-06-21 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
US6414218B1 (en) 2000-01-18 2002-07-02 The General Hospital Corporation Mouse model for rheumatoid arthritis
AU2001266604A1 (en) 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
JP4596916B2 (ja) 2002-09-05 2010-12-15 メディミューン,エルエルシー Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
CN1771055A (zh) * 2002-09-05 2006-05-10 免疫医疗公司 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法
US20040229785A1 (en) 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
US7510877B2 (en) 2003-09-26 2009-03-31 The Regents Of The University Of Michigan Hematopoietic stem cell identification and isolation
JPWO2005035578A1 (ja) 2003-10-09 2007-11-22 協和醗酵工業株式会社 ガングリオシドgm2に特異的に結合する抗体組成物
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
US8563308B2 (en) 2004-03-10 2013-10-22 The Rockefeller University Culture-expanded T suppressor cells and methods of use thereof
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN101084014A (zh) 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US20080102054A1 (en) 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
CA2605253C (en) 2005-04-11 2017-06-13 Yale University Selective modulation of tumour necrosis factor receptors in therapy
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
JP2010531138A (ja) 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性t細胞ならびに同製造および使用方法
US8900816B2 (en) 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
WO2009129538A2 (en) 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用
WO2010124262A1 (en) 2009-04-24 2010-10-28 Allostera Pharma Inc. Methods of identification of allosteramers and uses thereof
KR20120005460A (ko) 2009-04-28 2012-01-16 베링거 인겔하임 인터내셔날 게엠베하 Pkc-세타 억제제를 사용하는 면역학적 장애의 생체외 치료
US8530392B2 (en) 2009-05-13 2013-09-10 Shionogi & Co., Ltd. Test agent for visceral obesity and use thereof
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
WO2011107989A1 (en) 2010-03-01 2011-09-09 Lostam Biopharmaceuticals Ltd Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
KR101871008B1 (ko) 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
WO2012058137A2 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
EP2468764A1 (en) 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
WO2012122464A1 (en) 2011-03-10 2012-09-13 New York University Methods and compositions for modulating tnf/tnfr signaling
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2013165982A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-human cytomegalvirus antibodies and use thereof
US9531457B2 (en) 2012-07-18 2016-12-27 Kyocera Corporation Interference management of device-to-device communication in a cellular communication system
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション T制御性細胞の増殖または枯渇方法
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
EP3180087B1 (en) 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
US9172855B1 (en) 2014-08-28 2015-10-27 Avigilon Corporation Pendant housing for a camera
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
KR20250007678A (ko) * 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
SG10201912556VA (en) * 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
IL307684B2 (en) * 2016-09-29 2025-04-01 Amgen Inc Low viscosity antigen binding proteins and methods for preparing them
JP7054209B2 (ja) 2016-11-21 2022-04-13 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
AU2017384528A1 (en) * 2016-12-19 2019-07-04 Ichnos Sciences SA Novel TNFR agonists and uses thereof
WO2019094559A2 (en) 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
WO2021231922A1 (en) 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides

Also Published As

Publication number Publication date
WO2020041361A1 (en) 2020-02-27
CN112955179A (zh) 2021-06-11
CA3109954A1 (en) 2020-02-27
US20210340268A1 (en) 2021-11-04
JP7713880B2 (ja) 2025-07-28
EP3840782A1 (en) 2021-06-30
JP2025118591A (ja) 2025-08-13
JP2021534757A (ja) 2021-12-16
KR20210061350A (ko) 2021-05-27
EP3840782A4 (en) 2022-06-08
US12624117B2 (en) 2026-05-12
AU2019324134A1 (en) 2021-04-15
US20230295326A1 (en) 2023-09-21
AU2019324134B2 (en) 2026-05-07

Similar Documents

Publication Publication Date Title
US20250066494A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20240270860A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20230295326A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US12152082B2 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20220348645A1 (en) Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
US20240101693A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2025122817A1 (en) Antagonistic cd40 antibodies
HK40101997A (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HK1261204A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HK1261204B (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)